Introduction {#s1}
============

Cigarette smoking is a prominent risk factor for many respiratory diseases including emphysema/COPD, respiratory bronchiolitis, interstitial lung disease, and desquamative interstitial pneumonitis [@pone.0044066-Heguy1], [@pone.0044066-Shaykhiev1], [@pone.0044066-Vlahos1]. In fact, a correlation exists between alveolar macrophage numbers and the severity of COPD [@pone.0044066-Hogg1], [@pone.0044066-Finkelstein1], [@pone.0044066-Barnes1], [@pone.0044066-Shapiro1]. Aberrant gene expression in alveolar macrophages has been shown to alter the protease/anti-protease balance in the lung contributing to the development of emphysema [@pone.0044066-Shapiro1], [@pone.0044066-Hautamaki1], [@pone.0044066-Shapiro2], [@pone.0044066-Shapiro3]. Of particular importance in maintaining the optimal protease/anti-protease balance is expression of matrix metalloproteinase 12 (MMP12), a macrophage secreted enzyme that degrades elastin. The importance of alveolar macrophage-derived MMP12 in emphysema is well described [@pone.0044066-Hautamaki1], [@pone.0044066-Hunninghake1].

Alveolar macrophages are essential immune effector cells in the lung with functions that include pathogen clearance and responses to inhaled environmental exposures [@pone.0044066-Hautamaki1], [@pone.0044066-Bitterman1], [@pone.0044066-Bitterman2], [@pone.0044066-Houghton1], [@pone.0044066-Venet1], [@pone.0044066-Wert1]. Smoking causes alveolar macrophage defects in phagocytosis, responses to pathogen-associated molecular patterns, and microbicidal activity [@pone.0044066-Berenson1], [@pone.0044066-Chen1], [@pone.0044066-Hodge1], [@pone.0044066-King1], [@pone.0044066-Russell1]. These defects compromise alveolar macrophage-mediated protection from infectious agents [@pone.0044066-Stampfli1].

Macrophage gene expression programs are altered in response to local environmental cues. These changes may underlie the regulatory role macrophages play in many disease processes [@pone.0044066-Mosser1]. The use of polarizing stimuli to activate macrophages *in vitro* identified unique macrophage gene expression programs and the associated activation phenotypes. For example, exposure to inflammatory stimuli such as IFNγ and LPS polarizes macrophages toward an M1 activated phenotype that is associated with microbicidal activity [@pone.0044066-Mosser1]. Alternatively, macrophages can be polarized to a variety of M2 phenotypes after exposure to IL-4, immune complexes, IL-10, TGFβ, or steroids [@pone.0044066-Mantovani1]. Depending on the stimulus, the M2 phenotypes are associated with many activities including wound healing, immunosuppression, or production of cytokines promoting type 2 immune responses.

Transcriptional profiles of human alveolar macrophages directly isolated from nonsmokers and active smokers have shown that cigarette smoke exposure alters macrophage gene expression [@pone.0044066-Heguy1], [@pone.0044066-Shaykhiev1], [@pone.0044066-Woodruff1]. The pattern in alveolar macrophages from smokers has been suggested to reflect both suppression of M1-induced transcripts and increased expression of M2-induced transcripts [@pone.0044066-Shaykhiev1]. The data shown here, partially replicates this finding, while proposing a new definition of the altered phenotype in smoker alveolar macrophages.

MicroRNAs (miRNAs) are small, noncoding RNAs that have an important regulatory role in gene expression programs [@pone.0044066-Bartel1], [@pone.0044066-Ventura1], [@pone.0044066-Guo1]. Inhibition of translation and degradation of the miRNA-targeted transcripts occurs when a miRNA guides an RNA-induced silencing complex to the targeted transcript via miRNA:mRNA base pairing [@pone.0044066-Djuranovic1]. Each miRNA has the potential to repress the expression of hundreds of genes [@pone.0044066-Lim1]. Expression profiling has identified miRNAs that have increased abundance in macrophages responding to inflammatory conditions [@pone.0044066-Taganov1], [@pone.0044066-Androulidaki1], [@pone.0044066-OConnell1], [@pone.0044066-Ruggiero1], [@pone.0044066-Tili1], [@pone.0044066-Tserel1]. Despite an incomplete understanding of all transcripts targeted by the inflammation-induced miRNAs, several are known to regulate components of important signaling pathways involved in macrophage gene expression [@pone.0044066-Taganov1], [@pone.0044066-Lu1], [@pone.0044066-Nahid1], [@pone.0044066-ONeill1], [@pone.0044066-Tang1].

An initial study on the effect of smoking on human miRNA expression was reported by Schembri et al [@pone.0044066-Schembri1]. They identified 28 differentially expressed miRNAs when comparing primary human bronchial airway epithelium of smokers and nonsmokers. The effect of smoking on miRNA expression in human alveolar macrophages is unknown. We hypothesized that miRNAs have a role in regulating the unique gene expression program in alveolar macrophages of cigarette smokers. We examined miRNA and mRNA expression in alveolar macrophage RNA from active smokers and nonsmokers. Microarray-derived mRNA expression profiles suggested that smoking is associated with an inverse M1-type gene expression pattern in alveolar macrophages. Expression analysis of miRNAs showed a smoking dose-dependent global repression of miRNAs in alveolar macrophages. Target prediction analyses revealed many examples of downregulated miRNAs in smokers that correlated with increased expression of predicted mRNA targets. *In vitro* experiments showed a direct link between low expression of miR-452 and increased expression of MMP12 mRNA. These results are consistent with the hypothesis that miRNAs play a role in regulating gene expression in alveolar macrophages of smokers, and possibly a corresponding role in disease pathogenesis.

10.1371/journal.pone.0044066.t001

###### 25 most upregulated mRNAs in alveolar macrophages of smokers.

![](pone.0044066.t001){#pone-0044066-t001-1}

  Gene                                     Description                                Fold Change[a](#nt101){ref-type="table-fn"}   Smoker AMs[b](#nt102){ref-type="table-fn"}   M1[c](#nt103){ref-type="table-fn"}   M2a[c](#nt103){ref-type="table-fn"}
  ----------- ---------------------------------------------------------------------- --------------------------------------------- -------------------------------------------- ------------------------------------ -------------------------------------
  PLA2G7                           phospholipase A2, group VII                                           9.85                                           up                                      down                                 down
  SPP1                       secreted phosphoprotein 1 (osteopontin)                                     8.98                                           up                                      down                               no change
  CYP1B1              cytochrome P450, family 1, subfamily B, polypeptide 1                              8.63                                           up                                      down                               no change
  ATP6V0D2           ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d2                            8.41                                           up                                       ND                                   ND
  SLC7A11                    solute carrier family 7, member 11 (xCT)                                    6.36                                           up                                      down                                 down
  MMP12                  matrix metallopeptidase 12 (macrophage elastase)                                5.83                                           up                                       up                                   up
  FABP3                            fatty acid binding protein 3                                          5.39                                           up                                      down                               no change
  RPL15                               ribosomal protein L15                                              5.18                                       no change                                   down                               no change
  FLT1                        fms-related tyrosine kinase 1 (VEGFR)                                      5.13                                           up                                   no change                             no change
  A2M                                 alpha-2-macroglobulin                                              4.36                                           up                                      down                               no change
  UCHL1                      ubiquitin carboxyl-terminal esterase L1                                     3.79                                           up                                   no change                             no change
  S100B                           S100 calcium binding protein B                                         3.53                                           up                                   no change                                up
  CA2                                 carbonic anhydrase II                                              3.34                                           up                                      down                                   0
  SLC16A6      solute carrier family 16, member 6 (monocarboxylic acid transporter)                      3.28                                           up                                      down                                  up
  SSBP3                       single stranded DNA binding protein 3                                      3.25                                           up                                   no change                             no change
  TDRD9                             tudor domain containing 9                                            3.18                                           up                                   no change                             no change
  OR6N2                olfactory receptor, family 6, subfamily N, member 2                               3.15                                           ND                                       ND                                   ND
  HIST1H2AJ                          histone cluster 1, H2aj                                             3.13                                       no change                                    ND                                   ND
  C4orf18               chromosome 4 open reading frame 18 (DKFZp434L142)                                 3.1                                           up                                      down                               no change
  DNASE2B                           deoxyribonuclease II beta                                            3.07                                           up                                   no change                             no change
  SDC2                                      syndecan 2                                                   3.07                                           up                                      down                                  up
  MGST1                       microsomal glutathione S-transferase 1                                     3.03                                           up                                       up                                  down
  AGPAT9                  1-acylglycerol-3-phosphate O-acyltransferase 9                                 2.91                                           up                                      down                                 down
  TM7SF4                  transmembrane 7 superfamily member 4 (DCSTAMP)                                 2.75                                           up                                   no change                             no change
  LIPA                    lipase A, lysosomal acid, cholesterol esterase                                 2.71                                           up                                      down                               no change

Change indicates smoker-to-nonsmoker expression ratio in alveolar macrophages from this study.

Expression change of indicated mRNA described by Woodruff et al [@pone.0044066-Woodruff1] in analysis of alveolar macrophage smokers and nonsmokers (GEO dataset 1269).

Expression change of indicated mRNA described by Martinez et al [@pone.0044066-Martinez2] in analysis of monocyte-derived macrophages (MDMs) polarized toward M1 or M2a phenotypes relative to unstimulated MDMs (GEO datasets 2429 and 2430).

("up" indicates upregulation; "down" indicates downregulation; "no change" indicates no change and "ND" indicates not determined).

10.1371/journal.pone.0044066.t002

###### 25 most downregulated mRNAs in alveolar macrophages of smokers.

![](pone.0044066.t002){#pone-0044066-t002-2}

  Gene                                      Description                                 Fold Change[a](#nt105){ref-type="table-fn"}   Smoker AMs[b](#nt106){ref-type="table-fn"}   M1[c](#nt107){ref-type="table-fn"}   M2a[c](#nt107){ref-type="table-fn"}
  ---------- ------------------------------------------------------------------------- --------------------------------------------- -------------------------------------------- ------------------------------------ -------------------------------------
  CXCL11                         chemokine (C-X-C motif) ligand 11                                        −13.14                                         down                                      up                                no change
  CXCL9                          chemokine (C-X-C motif) ligand 9                                          −6.59                                         down                                      up                                no change
  SLC19A3                 solute carrier family 19 (thiamine transporter)                                  −5.93                                         down                                  no change                             no change
  EMR1        egf-like module containing, mucin-like, hormone receptor-like 1 (F4/80)                       −5                                           down                                      up                                no change
  CXCL10                         chemokine (C-X-C motif) ligand 10                                         −4.97                                         down                                      up                                no change
  PDGFD                          platelet derived growth factor D                                          −4.65                                         down                                  no change                             no change
  IGF1                             insulin-like growth factor 1                                            −4.47                                         down                                     down                               no change
  GBP5                              guanylate binding protein 5                                            −4.03                                         down                                      up                                no change
  OVCH1                                    ovochymase 1                                                    −3.86                                          ND                                       ND                                   ND
  C8B                              complement component 8, beta                                            −3.78                                         down                                  no change                             no change
  CD69                                     CD69 molecule                                                   −3.61                                         down                                  no change                             no change
  WDR49                                 WD repeat domain 49                                                −3.32                                         down                                      ND                                   ND
  TNFSF10          tumor necrosis factor (ligand) superfamily,member 10 (TRAIL)                            −3.27                                         down                                      up                                no change
  IFI27                   interferon, alpha-inducible protein 27 (ISG12)                                   −3.17                                         down                                      up                                   up
  TRHDE                   thyrotropin-releasing hormone degrading enzyme                                   −2.99                                         down                                  no change                             no change
  MYB                       v-myb myeloblastosis viral oncogene homolog                                    −2.97                                         down                                  no change                             no change
  GZMA                                      granzyme A                                                     −2.82                                      no change                                    up                                no change
  CLDN6                                      claudin 6                                                     −2.67                                      no change                                no change                             no change
  ARHGAP24                       Rho GTPase activating protein 24                                          −2.64                                         down                                  no change                             no change
  RXFP2                   relaxin/insulin-like family peptide receptor 2                                   −2.63                                      no change                                    ND                                   ND
  TRPC6          transient receptor potential cation channel,subfamily C, member 6                         −2.59                                         down                                  no change                             no change
  KLRK1               killer cell lectin-like receptor subfamily K, member 1                               −2.55                                      no change                                no change                             no change
  MS4A6A                membrane-spanning 4-domains, subfamily A,member 6A                                 −2.54                                      no change                                   down                               no change
  GBP3                              guanylate binding protein 3                                            −2.52                                      no change                                    up                                no change
  ITIH5                         inter-alpha (globulin) inhibitor H5                                        −2.52                                         down                                  no change                             no change

Change indicates smoker-to-nonsmoker expression ratio in alveolar macrophages from this study.

Expression change of indicated mRNA described by Woodruff et al [@pone.0044066-Woodruff1] in analysis of alveolar macrophage smokers and nonsmokers (GEO dataset 1269).

Expression change of indicated mRNA described by Martinez et al [@pone.0044066-Martinez2] in analysis of monocyte-derived macrophages (MDMs) polarized toward M1 or M2a phenotypes relative to unstimulated MDMs (GEO datasets 2429 and 2430).

("up" indicates upregulation; "down" indicates downregulation; "no change" indicates no change and "ND" indicates not determined).

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

All procedures and protocols described in this communication were approved by the University of Iowa Institutional Review Board. Written informed consent was obtained and all clinical investigation has been conducted according to the principles expressed in the Declaration of Helsinki.

Alveolar Macrophage Donors {#s2b}
--------------------------

Subjects were recruited from the community by the Iowa Institute for Clinical and Translational Science (ICTS) Clinical Core via advertisements and word-of-mouth. Inclusion criteria for case subjects required at least a 10 pack-year history of smoking, while the nonsmoker control subjects were self-reported never smokers. Subjects were excluded if they had any significant co-morbid conditions such as pregnancy or other acute or chronic disease such as pre-existing asthma, interstitial lung disease or cardiovascular disease. Subjects were also excluded if a baseline spirometry revealed the forced expiratory volume in the first second was less than 60% of the predicted value based on National Health and Nutrition Examination Survey III data set.

### Cohort 1 {#s2b1}

The first cohort of alveolar macrophage donors consisted of 4 nonsmokers and 4 active smokers with 31±14 pack-year histories. All subjects were Caucasian. The nonsmoker group had 3 males and 1 female with a mean group age of 26±9 years. The smoker group had 2 males and 2 females with a mean group age of 51±8 years.

### Cohort 2 {#s2b2}

The second cohort included 4 nonsmokers and 4 smokers with 31±3 pack-year histories. All subjects were Caucasian except for 1 African American in the smoker group. The nonsmoker group had 2 females and 2 males with a mean group age of 31±6 years. The smoker group had 2 males and 2 females with a mean age of 47±years.

### Cohort 3 {#s2b3}

The third cohort included 4 nonsmokers, 4 light smokers (12±2 pack-year histories), and 4 heavy smokers (33±6 pack-year histories). All subjects were Caucasian except for 1 African American in each of the smoker groups. Each of the three groups had 2 male and 2 female donors. The mean age for the groups was 35±12 years for the nonsmokers, 36±7 years for the light smokers, and 51±7 years for the heavy smokers.

Bronchoalveolar Lavage {#s2c}
----------------------

After informed consent was obtained, subjects underwent standard flexible bronchoscopy [@pone.0044066-Reisetter1]. Local anesthesia with lidocaine instillation into the upper airway was followed by bronchoalveolar lavage whereby 20 ml of normal saline was instilled into a tertiary bronchus up to five times in three different lung segments. The first collection out of five was discarded to avoid possible contamination with upper airway secretions or lidocaine. The remaining lavage was filtered through sterile gauze and centrifuged at 200×g for 5 minutes to pellet cellular material. The resulting pellet was suspended in phosphate buffered saline (PBS) and centrifuged at 200×g for 5 minutes. A sample of the cells were labeled with Wright stain and microscopically examined to determine the proportion of the cells that were macrophages [@pone.0044066-Monick1], [@pone.0044066-Monick2], [@pone.0044066-Monick3], [@pone.0044066-Monick4]. Aliquots of 5×10^6^ cells were stored at −80°C until RNA isolation procedure was performed. Cell yields from bronchoscopy in cohort 1 averaged 25±3×10^6^ cells for the nonsmokers and 67±4×10^6^ cells for the active smokers. In all three cohorts the procedure generated a relatively pure population of alveolar macrophages with fewer than 5% neutrophils or lymphocytes in the bronchoalveolar lavage fluid.

![Expression profiling indicates similar numbers of mRNAs are upregulated and downreglated in alveolar macrophages of cigarette smokers and nonsmokers.\
Smoker-to-nonsmoker mRNA expression ratios were determined using RNA from alveolar macrophages as template in GeneChip Human Exon 1.0 ST cDNA microarrays (Affymetrix). The RNA was collected from alveolar macrophages directly isolated from four nonsmokers and four smokers (cohort 1). **A)** Smoker-to-nonsmoker expression ratios are represented by black circles in order from lowest to highest for the 17,860 detected cDNAs. The arrow indicates the point where specific mRNA expression ratios in smokers and nonsmokers = 1. **B)** The expression ratios are shown for several commonly used endogenous controls. (ACTB = actin, beta; B2M = beta-2-microglobulin; GAPDHS = glyceraldehyde-3-phosphate dehydrogenase, spermatogenic; PGK1 = phosphoglycerate kinase 1; peptidylprolyl isomerase A; RPLP0 = ribosomal protein, large, P0; TBP = TATA box-binding protein).](pone.0044066.g001){#pone-0044066-g001}

RNA Isolation {#s2d}
-------------

RNA was isolated from alveolar macrophages or PMA-differentiated THP-1 cells using the mirVana miRNA Isolation kit (Applied Biosystems (ABI)). The quantity and quality of the RNA samples was assessed using an Experion Automated Electrophoresis Station (Bio-Rad). The RNA quality indicator was above 8 for all samples where values of greater than 8 indicate primarily intact RNA on a scale of 1--10. After preparation, RNA samples were stored at −80°C until use.

mRNA Expression Analysis {#s2e}
------------------------

Measurements of genome-wide macrophage mRNA expression were conducted using the GeneChip Human Exon 1.0 ST Arrays (Affymetrix). Generation of labeled cDNA, hybridizations, and scanning of the microarray were performed under contract by the University of Iowa DNA facility. The resulting data were analyzed using the Partek Genomics Suite version 6.5 (Partek). The data were assessed for quality and subjected to robust multiarray averaging (RMA) normalization. The normalized data were then analyzed using an ANOVA model with linear contrasts to calculate p-values and smoker-to-nonsmoker expression ratios. The false discovery rate (FDR) step-up method [@pone.0044066-Benjamini1] was applied to correct for multiple testing. The expression data has been deposited in NCBI Geo repository (GSE34517).

miRNA Expression Analysis {#s2f}
-------------------------

RNA from alveolar macrophages of nonsmokers and active smokers was reverse transcribed with MultiScribe Reverse Transcriptase (ABI) using Megaplex Primers version 2.0 (ABI). Changes in miRNA expression was then determined using human TaqMan Low Density Arrays version 2.0 (ABI). Ct values calculated using SDS version 2.4 (ABI) were exported to the Partek Genomics Suite to calculate smoker-to-nonsmoker expression ratios. RMA-normalized data were subjected to an ANOVA model with linear contrasts to calculate p-values.

Principle component analysis (PCA) was performed using standard functions built in MATLAB software version 7.9 (MathWorks). This analysis identified a representative miRNA within each cluster with the highest Pearson correlation between its expression profile and the first principal component from our PCA analysis [@pone.0044066-Langfelder1]. Cluster analysis was performed using ΔCt values of the miRNAs with expression changes of \>2-fold was accomplished using the CiMminer web interface and the default Euclidean clustering algorithm (<http://discover.nci.nih.gov/cimminer/>).

![Expression profiling indicates a global repression of total miRNA abundance in alveolar macrophages of cigarette smokers.\
Smoker-to-nonsmoker miRNA expression ratios were determined using RNA from alveolar macrophages as template in TaqMan Low Density Array v2.0 RT-qPCR assays (ABI). The endogenous control, RNU48, was used to normalize the data. The eight RNA samples used as template in [figure 1](#pone-0044066-g001){ref-type="fig"} were also used in these TLDA assays (cohort 1). **A)** Smoker-to-nonsmoker expression ratios are represented by black circles in order from lowest to highest for the 481 detected miRNAs. The arrow indicates the point where miRNA expression ratios in smokers and nonsmokers = 1. **B)** The expression ratios are shown for three additional endogenous control options provided with the TLDA assay are shown. **C)** The expression ratios and p-values of the 481 detected miRNAs are shown using a volcano plot. The significantly upregulated (red) and downregulated (blue) miRNAs are indicated along with the endogenous controls (green). **D)** The 54 miRNAs with smokers-to-nonsmokers expression ratios greater than 2 are shown following principle component analysis (PCA) with MATLAB software. This analysis identified a representative miRNA within each cluster with the highest Pearson correlation between its expression profile and the first principal component from our PCA analysis. **E)** Clustering analysis of the 54 regulated miRNAs was performed using CiMminer based on ΔCt-values of the TLDA results. The 4 clusters identified by PCA are labeled. Upregulated miRNAs are designated by various shades of red and downregulated miRNAs by various shades of blue.](pone.0044066.g002){#pone-0044066-g002}

Validation of Changes in Individual miRNAs {#s2g}
------------------------------------------

Validation studies were performed using alveolar macrophage RNA collected from the initial array group (cohort 1) and a non-redundant sample set (cohort 2). Individual TaqMan MicroRNA Assays corresponding to assays including in the TLDA version 2.0 assays (ABI) were used to document abundance of the mature forms of three of the downregulated miRNAs. Briefly, 10 ng RNA was reversed transcribed with MultiScribe RT (ABI) using a miRNA-specific stem loop primer. Then, PCR with TaqMan Universal PCR Master Mix (ABI) was performed using miRNA-specific real time primers. Expression levels were defined as a ratio between the Ct values of the indicated miRNA and the endogenous control, RNU48.

Analysis of miRNA Target Prediction Expression {#s2h}
----------------------------------------------

Using the Partek Genomics Suite software, each indicated miRNA was used to query the TargetScan [@pone.0044066-Lewis1] and MicroCosm [@pone.0044066-GriffithsJones1] databases to identify predicted targets. The smoker-to-nonsmoker expression ratio and ANOVA-derived p-value of each predicted miRNA target were exported from the GeneChip Human Exon microarray results to an Excel spreadsheet (Microsoft). Excel was used to filter data by expression ratios and p-values.

Expression of Predicted Targets in miRNA Antagonist-transfected THP-1 Cells {#s2i}
---------------------------------------------------------------------------

THP-1 cells were maintained in RPMI 1640 (Gibco) supplemented with fetal bovine serum (10%; Gibco). Cells were incubated with PMA (5 ng/ml; Sigma-Aldrich) for 18 hours to induce differentiation toward a macrophage phenotype [@pone.0044066-Tsuchiya1]. They were then transfected with the miR-452 or negative control mirVana miRNA Inhibitors (25 nM; ABI) using RNAiMAX (Invitrogen). RNA was purified from cell lysates collected at 24 hours post-transfection. Total RNA (300 ng) was reverse-transcribed to cDNA using iScript cDNA Synthesis kit (Bio-Rad). SYBR Green-based quantitative PCR reactions (BioRad) were performed as previously described [@pone.0044066-Hansdottir1]. Specificity of the amplification was confirmed using melting curve analysis. Expression levels were defined as a ratio between the threshold cycle (Ct) values of MMP12 or TM7SF4 and the endogenous control, HPRT. The primers (Integrated DNA Technologies) used in the PCR reactions were: MMP12, forward 5′-aggtggaatcctagcccatgcttt-3′, reverse 5′-tcaggatttggcaagcgttggttc-3′; TM7SF4, forward 5′-tgggagtttgctgtttggttgctc-3′, reverse 5′-atcaaagcattcctgccttcacgc-3′; HPRT, forward 5′-ccatcacattgtagccctctgtgt-3′, reverse 5′-actgcctgaccaaggaaagcaaag-3′.

10.1371/journal.pone.0044066.t003

###### miRNAs upregulated \>2-fold in alveolar macrophages of smokers.

![](pone.0044066.t003){#pone-0044066-t003-3}

  miRNA          miRNA Family   Polycistronic miRNA Precursor   Fold Change   p-value
  ------------- -------------- ------------------------------- ------------- ---------
  miR-132\*        miR-132               miR-132/212               78.47      0.0002
  miR-139-3p         N/A                     N/A                    52        0.0151
  miR-548c-3p      miR-548              miR-548c/548z              16.71      0.0357
  miR-211          miR-204                   N/A                   15.77      0.0355
  miR-222\*        miR-221               miR-221/222               15.3       0.0082
  miR-221          miR-221               miR-221/222               12.59      0.0005
  miR-221\*        miR-221               miR-221/222               5.77        0.009
  miR-222          miR-221               miR-221/222               5.42       0.0006
  miR-132          miR-132               miR-132/212               3.05       0.0017
  miR-212          miR-132               miR-132/212               2.58       0.0102

10.1371/journal.pone.0044066.t004

###### miRNAs downregulated \>2-fold in alveolar macrophages of smokers.

![](pone.0044066.t004){#pone-0044066-t004-4}

  miRNA          miRNA Family[a](#nt109){ref-type="table-fn"}   Polycistronic miRNA Precursor[b](#nt110){ref-type="table-fn"}   Fold Change[c](#nt111){ref-type="table-fn"}   p-value
  ------------- ---------------------------------------------- --------------------------------------------------------------- --------------------------------------------- ---------
  miR-452                          miR-452                                             miR-224/miR-452                                            −1030.3                     \<0.001
  miR-129-3p                         N/A                                                     N/A                                                  −414.23                      0.004
  miR-31                             N/A                                                     N/A                                                  −326.38                      0.005
  miR-34b\*                         miR-34                                             miR-34b/miR-34c                                            −96.89                       0.037
  miR-210                            N/A                                                     N/A                                                  −84.03                       0.007
  miR-200b\*                        miR-8                                         miR-200a/miR-200b/miR-429                                       −71.68                       0.002
  miR-150                            N/A                                                     N/A                                                  −70.28                       0.001
  miR-449a                         miR-449                                       miR-449a/miR-449b/miR-449c                                       −49.46                       0.018
  miR-200a                          miR-8                                         miR-200a/miR-200b/miR-429                                       −45.64                       0.011
  miR-10b                           miR-10                                                   N/A                                                  −42.63                       0.005
  miR-449b                         miR-449                                       miR-449a/miR-449b/miR-449c                                       −33.37                       0.047
  miR-224                          miR-452                                             miR-224/miR-452                                            −32.41                      \<0.001
  miR-708                            N/A                                                     N/A                                                  −26.52                      \<0.001
  let-7b\*                          let-7                                         let-7a-3/let-7b/miR-4763                                         −25.9                       0.044
  miR-149                            N/A                                                     N/A                                                  −17.34                       0.019
  miR-187                            N/A                                                     N/A                                                  −12.18                       0.001
  miR-125a-5p                      miR-125                                         let-7e/miR-99b/miR-125a                                         −7.64                       0.001
  miR-130\*                        miR-130                                                   N/A                                                   −6.56                       0.035
  miR-363                          miR-363                                           miR-106a-92 cluster                                           −6.3                        0.004
  miR-99a\*                         miR-99                                             let-7c/miR-99a                                              −6.15                       0.003
  miR-99b                           miR-99                                         let-7e/miR-99b/miR-125a                                         −4.6                        0.019
  miR-10a                           miR-10                                                   N/A                                                   −4.55                       0.008
  miR-95                            miR-95                                                   N/A                                                   −4.23                       0.003
  miR-489                            N/A                                               miR-489/miR-653                                             −3.5                        0.005
  miR-429                           miR-8                                         miR-200a/miR-200b/miR-429                                        −3.36                       0.05
  miR-939                            N/A                                                  miR-1234                                                 −3.15                       0.045
  miR-642                          miR-642                                                   N/A                                                   −3.11                       0.04
  miR-99b\*                         miR-99                                         let-7e/miR-99b/miR-125a                                         −3.1                        0.027
  miR-200b                          miR-8                                         miR-200a/miR-200b/miR-429                                        −2.94                       0.03
  let-7i\*                          let-7                                                    N/A                                                   −2.87                       0.023
  miR-99a                           miR-99                                             let-7c/miR-99a                                              −2.78                       0.017
  miR-106b                          miR-17                                         miR-25/mir-93/miR-106b                                          −2.78                       0.033
  miR-100                           miR-99                                            let-7a-2/miR-100                                             −2.73                       0.014
  miR-589                            N/A                                                     N/A                                                   −2.65                       0.022
  miR-15a\*                         miR-15                                            miR-15a/miR-16-1                                             −2.61                       0.049
  miR-146b-3p                      miR-146                                                   N/A                                                   −2.49                      \<0.001
  miR-125b                         miR-125                                                   N/A                                                   −2.48                       0.008
  miR-601                            N/A                                                     N/A                                                   −2.38                       0.005
  miR-630                            N/A                                                     N/A                                                   −2.34                       0.025
  miR-146b-5p                      miR-146                                                   N/A                                                   −2.2                        0.006
  miR-223\*                          N/A                                                     N/A                                                   −2.18                       0.037
  miR-454\*                          N/A                                                     N/A                                                   −2.14                       0.034
  miR-193b                         miR-193                                            miR-193b/miR-365a                                            −2.07                       0.043

Family names as specified by miRBase release 18.

Clustered miRNAs described in miRBase release 18 were assumed to be polycistronic pri-miRNAs.

Fold change indicates miRNA expression in alveolar macrophages of smokers compared to nonsmokers.

Results {#s3}
=======

Alveolar Macrophages from Smokers Displayed an "Inverse" M1 Gene Expression Profile {#s3a}
-----------------------------------------------------------------------------------

Cigarette smoking has been shown to alter the transcriptional profile of human alveolar macrophages in a consistent manner as reported by two independent groups [@pone.0044066-Heguy1], [@pone.0044066-Shaykhiev1], [@pone.0044066-Woodruff1]. Prior to measuring miRNA expression in alveolar macrophages from four normal healthy subjects and four cigarette smokers (cohort 1), microarrays were performed to compare the transcriptional profile of these donors to previous reports.

[Tables 1](#pone-0044066-t001){ref-type="table"} and [2](#pone-0044066-t002){ref-type="table"} display the most upregulated and downregulated mRNAs, respectively, with p-values \<0.05 in alveolar macrophages from smokers compared to nonsmokers. These regulated genes were compared to an independent mRNA expression profiling study in alveolar macrophages from 15 smokers and 15 nonsmokers by Woodruff et al., summarized in the 4^th^ column of [Tables 1](#pone-0044066-t001){ref-type="table"} and [2](#pone-0044066-t002){ref-type="table"} ([@pone.0044066-Woodruff1] and GEO dataset GDS1269). Results from our study were in strong agreement with this previous study. Most of the highly regulated mRNAs were similarly regulated in both studies and none of these mRNAs were regulated in the opposite direction (compare 3^rd^ and 4^th^ columns within [Tables 1](#pone-0044066-t001){ref-type="table"} and [2](#pone-0044066-t002){ref-type="table"}).

To further evaluate the extent to which the gene expression profile in alveolar macrophages from smokers contrasts with an M1 profile, the highly regulated mRNAs listed in [Tables 1](#pone-0044066-t001){ref-type="table"} and [2](#pone-0044066-t002){ref-type="table"} were compared to results reported by Martinez et al [@pone.0044066-Martinez1] that described the transcriptional profile of unstimulated, M1-polarized (IFNγ- and LPS-treated), and M2a-polarized (IL-4 treated) macrophages (GEO datasets GDS2429 and GDS2430). The alveolar macrophages from smokers have an "inverse" M1 gene expression profile because not only were mRNAs that are upregulated in M1 macrophages downregulated in alveolar macrophages from smokers, similar to the observations of Shaykhiev et al [@pone.0044066-Shaykhiev1], but also mRNAs downregulated by M1 polarization were often upregulated in smoker alveolar macrophages (compare 3^rd^ and 5^th^ columns within [Tables 1](#pone-0044066-t001){ref-type="table"} and [2](#pone-0044066-t002){ref-type="table"}). Unlike the M1-regulated mRNAs, there was not any discernible correlation between mRNAs regulated in alveolar macrophages in response to cigarette smoking and mRNAs regulated in macrophages in response to *in vitro* M2a-polarizing conditions.

![Expression profiling results were validated for select miRNAs in samples from the original alveolar macrophage donors and additional, non-redundant donors.\
Individual miRNA qRT-PCR expression assays were used to evaluate the expression of miR-146b-3p, miR-150, and miR-210. Expression of these miRNAs was determined using **A)** RNA analyzed previously in the TLDA assays (cohort 1) and **B)** RNA obtained from an independent set of donors (cohort 2). The mean expression with SEM of each miRNA is shown as a ratio to RNU48 for each sample.](pone.0044066.g003){#pone-0044066-g003}

A global mRNA abundance increase was reported in lung tissue from a rat model of cigarette smoking [@pone.0044066-Izzotti1]. Among the mRNAs with p-values \<0.05, more transcripts were upregulated in smoker alveolar macrophages relative to nonsmoker alveolar macrophages when using a 2-fold change cut-off. Specifically, 70 mRNAs were upregulated and 48 mRNAs were downregulated. However, when assessing all mRNAs detected by the microarrays, there were approximately equal numbers of mRNAs with smoker-to-nonsmoker expression ratios greater than 1 (51.2%) and less than 1 (48.8%) in the alveolar macrophage samples ([Figure 1A](#pone-0044066-g001){ref-type="fig"}) and the expression ratios of mRNAs commonly used as endogenous controls were each close to 1 ([Figure 1B](#pone-0044066-g001){ref-type="fig"}). While there were significant differences in expression of specific mRNAs, there was no apparent global shift in global mRNA levels in human alveolar macrophages of smokers and nonsmokers.

Total miRNA Abundance is Reduced in Smoker Alveolar Macrophages {#s3b}
---------------------------------------------------------------

To address our hypothesis that miRNAs have a role in maintaining the unique smoking-associated gene expression profile, we next obtained miRNA expression profiles. TaqMan Low Density Array (TLDA) assays were used to measure miRNA expression in the same RNA samples from alveolar macrophages of smokers and nonsmokers that had been used to analyze mRNA expression (cohort 1). TLDA assays use quantitative RT-PCR to specifically measure the abundance of 667 mature human miRNAs. The total miRNA abundance appeared to be lower in alveolar macrophages from cigarette smokers compared to nonsmokers, with a median expression ratio of 0.63. Therefore, the majority (75.7%) of miRNA smoker-to-nonsmoker expression ratios was less than 1 ([Fig 2A](#pone-0044066-g002){ref-type="fig"}). Interestingly, the general repression of miRNA expression in alveolar macrophages of cigarette smokers coincides with reports that cigarette smoke reduces overall miRNA expression in primary human epithelial cells [@pone.0044066-Schembri1] and in lung tissues of rats [@pone.0044066-Izzotti1].

The expression of miRNAs was determined using a small nucleolar RNA, RNU48, as an endogenous control. Three other small nucleolar RNAs (RNU24, RNU43, and RNU44) were included in the TLDA assays as alternative endogenous controls. The expression of all three of the additional controls was unchanged when calculated using RNU48 as an endogenous control ([Fig 2B](#pone-0044066-g002){ref-type="fig"}). The general repression of global miRNAs described in [figure 2A](#pone-0044066-g002){ref-type="fig"} is unlikely to be caused by an artifactual skewing of the data due to unreliable endogenous controls since all four endogenous controls available on the TLDA assays were in agreement with each other.

![Expression profiling of a second data set indicates a global repression of total miRNA abundance in alveolar macrophages of cigarette smokers.\
Nonsmoker, light smoker, and heavy smoker miRNA expression ratios were determined by TLDA assays using RNA from alveolar macrophages (cohort 3). The endogenous control, RNU48, was used to normalize the data. **A)** Smoker-to-nonsmoker expression ratios are represented by black circles (light smokers) and red circles (heavy smokers) in order from lowest to highest for 277 and 281 detected miRNAs, respectively. **B)** The number of miRNAs with a greater than 2-fold change between the two smoker groups and the nonsmokers are displayed.](pone.0044066.g004){#pone-0044066-g004}

The overall repression of miRNA expression in alveolar macrophages of smokers compared to nonsmokers was also observed when comparing the number of miRNAs with statistically significant (p\<0.05) abundance differences. For example, when using a 2-fold cut-off, 11 miRNAs have increased abundance and 43 miRNAs have decreased abundance ([Fig 2C](#pone-0044066-g002){ref-type="fig"}). General information for the upregulated and downregulated miRNAs is shown in [Table 3](#pone-0044066-t003){ref-type="table"} and [Table 4](#pone-0044066-t004){ref-type="table"}, respectively. We list 10 miRNAs in [Table 3](#pone-0044066-t003){ref-type="table"}, rather than the 11 in the data set because miR-923 is no longer considered a miRNA by miRBase. Principal component analysis (PCA) groups these 54 miRNAs into four clusters (Clusters 1--4) with the upregulated miRNAs and the downregulated miRNAs each separated into two clusters ([Fig 3D](#pone-0044066-g003){ref-type="fig"}). The PCA analysis identified a representative miRNA (miR-548c-3p, miR-139-3p, miR-489, and miR-454\*) for each of the four clusters. Although the significance is unclear, we note that clusters 2 and 4 are dominated by passenger strands while clusters 1 and 3 are dominated by guide miRNA strands ([Fig 3E](#pone-0044066-g003){ref-type="fig"}). miRNA passenger strands are the strand of each miRNA-duplex that is less likely to be loaded into the RNA-induced silencing complex (RISC) [@pone.0044066-Hansdottir1], [@pone.0044066-Martinez1].

10.1371/journal.pone.0044066.t005

###### Downregulated miRNAs in alveolar macrophages of smokers and corresponding predicted mRNA targets with upregulated expression.

![](pone.0044066.t005){#pone-0044066-t005-5}

  miRNA                                     Predicted mRNA target[a](#nt112){ref-type="table-fn"}
  ---------- -------------------------------------------------------------------------------------------------------------------
  miR-95                                                         PRSS21 (M)
  miR-99a                                                         UGCG (M)
  miR-99b                                                         UGCG (M)
  miR-100                                                         UGCG (M)
  miR-106b                                                      C10orf58 (M)
  miR-125b                           ATP13A3 (T), BCAT1 (T), C10orf58 (T), CSF (M), LIPA (T), TXNRD1 (T)
  miR-130a                                                 ATP13A3 (T), BCAT1 (T)
  miR-187                                               FAIM (M), MGST (M), UCHL1 (M)
  miR-193b                                                GCLC (M), SLC16A6 (M & T)
  miR-200b                                           CCDC102B (M), CYP1B1 (T), FLT1 (T)
  miR-363                                                          SLC16A1
  miR-429                            ATP13A3 (M), CCDC102B (M), CSF1 (M), CYP1B1 (T), FLT1 (T), SDC2 (T)
  miR-449a                                           C15orf48 (M), FABP3 (M), PRSS21 (M)
  miR-449b                                                 C15orf48 (M), FABP3 (M)
  miR-452     CCDC102B (M), GSR (M), **MMP12 (M),** MOSPD1 (M), SPRY2 (M), TDRD9 (M), **TM7SF4 (M),** C10orf58 (M), SLC7A11 (T)
  miR-601                                                          CA2 (M)
  miR-630                                 C15orf48 (M), CA2 (M), PLA2G7 (M), SLC04C1 (T), SPRY2 (M)
  miR-708                                                         CSF1 (T)

Gene symbols of putative miRNA targets with the prediction algorithm indicated within parenthesis ("M" = MicroCosm; "T" = TargetScan). Text in bold identifies genes tested in correlation assays (see [Figure 5](#pone-0044066-g005){ref-type="fig"}).

Individual RT-PCR miRNA assays were used to confirm the observations from the TLDA assays. Three differentially expressed miRNAs (miR-146b-3p, miR-150, and miR-210) were validated using the same RNA samples from cohort 1 analyzed in the TLDA assays ([Fig 3A](#pone-0044066-g003){ref-type="fig"}). Furthermore, these miRNAs were similarly regulated in a second, non-redundant set of alveolar macrophage samples (cohort 2) from nonsmokers and smokers ([Fig 3B](#pone-0044066-g003){ref-type="fig"}).

![Inhibition of miRNA-452 results in increased MMP12 expression.\
RNA was collected from PMA-differentiated THP1 cells at 24 hours post-transfection with either a control miRNA inhibitor or a miR-452 inhibitor. Quantitative RT-PCR was used to determine the expression of putative miR-452 target. The mean expression with SEM from three independent experiments is shown for MMP12 and TM7SF4 as a ratio to HPRT for each sample.](pone.0044066.g005){#pone-0044066-g005}

Decreased Global miRNA Expression is Associated with Heavy Smoking Histories {#s3c}
----------------------------------------------------------------------------

TLDA assays were used to evaluate miRNA expression profiles in a third set of alveolar macrophages (cohort 3). Four donors each were categorized as nonsmokers (no smoking history), light smokers, and heavy smokers. Light smoking resulted in a modest reduction in miRNA expression compared to nonsmokers with 54.2% of miRNAs have an expression ratio less than 1 relative to nonsmokers. The decrease in global miRNA expression was more pronounced in heavy smokers with expression ratios of less than 1 for 72.6% of the miRNAs ([Figure 4A](#pone-0044066-g004){ref-type="fig"}). The general downregulation of miRNAs in alveolar macrophages of smokers was also apparent by assessing the number of miRNAs using a 2-fold expression change cut-off ([Figure 4B](#pone-0044066-g004){ref-type="fig"}). These results from cohort 3 confirmed that smoking represses global miRNA expression and suggests that the amplitude of overall repression is directly related to the extent of an individuals' smoking history.

Inverse Correlations between Regulated miRNAs and the Expression of their Predicted mRNA Targets {#s3d}
------------------------------------------------------------------------------------------------

Most mRNAs targeted for repression by miRNAs are degraded [@pone.0044066-Guo1]. Therefore, using the results from cohort 1, the miRNAs with regulated expression were analyzed further to determine whether the expression of these miRNAs inversely correlated with the mRNA expression of their predicted targets. Using Partek Genomics Suite software, all targets predicted by either the MicroCosm or TargetScan algorithms for each miRNA were identified. Analysis of the expression for all predicted targets of each miRNA as calculated in the microarray experiments failed to reveal any examples in which a downregulated miRNA correlated with a global increase in its predicted targets, or conversely an upregulated miRNA correlated with a global decrease in its predicted targets (data not shown). There were, however, many instances in which downregulated miRNAs correlated with increased expression of a subset of predicted targets ([Table 5](#pone-0044066-t005){ref-type="table"}). There was only one upregulated miRNA family, miR-221, that was associated with a downregulated predicted target, IGF1.

To test our hypothesis that miRNAs influence the mRNA expression profiles in alveolar macrophages of cigarette smokers, we evaluated whether antagonizing the function of a specific miRNA would lead to increased mRNA expression of the predicted target. We were particularly interested in whether the highly downregulated miRNA, miR-452, influenced the expression of MMP12, a protease relevant to smoking-related diseases that is highly upregulated in alveolar macrophages of smokers. Transfecting in an inhibitor of miR-452 resulted in elevated expression of MMP12 transcripts, but had no effect on another predicted target of miR-452, TM7SF4 ([Figure 5](#pone-0044066-g005){ref-type="fig"}).

Discussion {#s4}
==========

This study reports on miRNA and mRNA expression in alveolar macrophages from nonsmokers and active cigarette smokers. Significant differences in both miRNA and mRNA expression were found in alveolar macrophages obtained from nonsmokers and smokers. We identified a smoking history-dependent decrease in global miRNA abundance. Importantly, we describe many examples of inverse relationships between miRNAs and their predicted mRNA targets and used an *in vitro* system to support our hypothesis that miRNAs influence the expression of an important macrophage product.

*In vitro* polarization of monocyte-derived macrophages (MDMs) leads to distinct phenotypes that have been categorized as M1, M2a, M2b, and M2c [@pone.0044066-Mantovani1], [@pone.0044066-Martinez2]. This classification system is useful, particularly in defining gene expression programs related to specific polarized phenotypes. However, the extent to which these phenotypes accurately depict macrophage phenotypes *in vivo* has been difficult to determine, partly because purification of human macrophages from the tissues in which they are embedded is usually not possible. Human alveolar macrophages are unique in this aspect since relatively pure populations can be obtained from bronchoalveolar lavage fluid. A consistent alteration in gene expression profiles of human alveolar macrophages from cigarette smokers compared to nonsmokers has been reported by two independent groups of investigators [@pone.0044066-Heguy1], [@pone.0044066-Shaykhiev1], [@pone.0044066-Woodruff1]. Despite a relatively small alveolar macrophage sample size, we were able to confirm a similar transcriptional expression profile with Woodruff et al [@pone.0044066-Woodruff1]. The gene expression profile of smoker alveolar macrophages was recently described as a "deactivated M1 polarization program" [@pone.0044066-Shaykhiev1]. We suggest that the gene expression program could best be described as an "inverse" M1 profile, because M1-induced mRNAs are less abundant and M1-repressed mRNAs were more abundant in alveolar macrophages of smokers relative to nonsmokers.

Since cigarette smoking is associated with increased risk of pulmonary infections [@pone.0044066-Stampfli2], understanding the mechanisms causing the inverse M1 phenotype in smoker alveolar macrophages might provide therapeutic targets for improving antimicrobial activity. Generation of M1-polarized MDMs *in vitro* is accomplished by treatment with two stimuli, typically IFNγ and either TNFα or another molecule that promotes TNFα production such as LPS [@pone.0044066-Mosser1], [@pone.0044066-Martinez2]. One possibility is that the inverse M1 phenotype described for smoker alveolar macrophages is due to a cigarette smoke-induced defect in TNFα- and/or IFNγ-induced signaling such as the NF-κB and JAK-STAT pathways. Indeed, impairment in IFNγ signaling has been described in alveolar macrophages and epithelial cells of cigarette smokers [@pone.0044066-Modestou1], [@pone.0044066-Dhillon1]. The mechanism responsible for impaired IFNγ signaling is unknown. Whether miRNAs play a role promoting the inverse M1 gene expression program is currently being investigated.

We hypothesized that miRNAs are at least partly responsible for regulating the unique gene expression profile in alveolar macrophages of smokers. The RNA samples collected from cohort 1 for mRNA expression profiling of smoker and nonsmoker alveolar macrophages were also used in TLDA miRNA profile assays to compare the abundance of 667 human miRNAs. This global approach to evaluating miRNA expression identified 54 miRNAs with significantly altered expression. Among the 10 miRNAs that were significantly upregulated by \>2-fold, 7 are located on two polycistronic pri-miRNAs, the miR-132/212 cluster and the miR-221/222 cluster. Therefore, increased transcription of these two polycistronic pri-miRNAs could explain almost all of the highly upregulated miRNAs in smoker alveolar macrophages. Similarly, transcriptional regulation may also be important for many of the significantly repressed miRNAs in smoker alveolar macrophages because ten downregulated miRNAs were processed from four polycistronic pri-miRNAs (miR-224/miR452, miR-200a/miR-200b/miR-429, miR-449a/miR-449b/miR-449c, and let-7e/miR-99b/miR-125a).

An important observation from the miRNA profiling experiments was that the majority of miRNAs with altered expression in alveolar macrophages of smokers compared to nonsmokers were downregulated. Functionally, this should lead to increased mRNA expression in targeted genes. Using both the TargetScan and MicroCosm target prediction algorithms to analyze the results from cohort 1, we found that 30 of the 70 statistically significant mRNAs upregulated by \>2-fold were putative targets of miRNAs that were significantly downregulated by \>2-fold. The most strongly downregulated miRNA in smokers, miR-452, had the most predicted targets with upregulated expression. In experiments utilizing a miR-452 inhibitor, we show that inhibition of this miRNA in differentiated THP-1 cells resulted in elevated MMP12 transcript expression.

It is likely that miRNAs are not the only mechanism that could contribute to the inverse M1 alveolar macrophage phenotype. For example, soluble TNF receptor type II is increased in the sputum of smokers with COPD [@pone.0044066-Pottelberge1] and in mouse models [@pone.0044066-DHulstA1]. This likely sequesters TNFα and dampens the effects of M1 polarizing stimuli. Furthermore, the transcript SPP1 (encoding osteopontin), is consistently highly upregulated in studies of smoker alveolar macrophages [@pone.0044066-Heguy1], [@pone.0044066-Shaykhiev1], [@pone.0044066-Woodruff1]. Osteopontin treatment of macrophages results in proteasome-mediated degradation of STAT1 [@pone.0044066-Gao1], [@pone.0044066-Guo2].

There was a striking ∼50--60% reduction in total miRNA abundance in alveolar macrophages of smokers relative to nonsmokers. Global repression of miRNA expression that was also noted using non-TLDA miRNA profiling platforms in epithelial cells of smokers and in lung tissue of rats in a model of cigarette smoking [@pone.0044066-Schembri1], [@pone.0044066-Izzotti1]. Furthermore, miRNA expression profiling in induced sputum of cigarette smokers and nonsmokers showed that the majority of differentially expressed miRNAs were downregulated [@pone.0044066-Pottelberge1], although the method of data analysis in this latter study prevented the authors from commenting on differences in global miRNA abundance between the two alveolar macrophage sample types.

The reduced global expression of miRNAs reported here in alveolar macrophages of smokers has also been reported for many cancers. For example, total miRNA abundance is lower in tumors and tumor-derived cell lines relative to corresponding normal tissue [@pone.0044066-Gaur1], [@pone.0044066-Lu2]. The initial studies of global miRNA repression in cancer noted that mRNAs encoding the miRNA processing machinery were not altered in cancer cells [@pone.0044066-Lu2]. Likewise, we detected no statistically significant changes in alveolar macrophages of smokers for transcripts encoding Dicer, Drosha, Ago1--4, DGCR8, TRBP, PACT, exportin-5, or GW182 (data not shown). The repression of miRNAs in cancer appears to be due to inefficient processing of primary miRNA transcripts [@pone.0044066-Thomson1]. The cigarette smoke-induced mechanism of global miRNA repression in alveolar macrophages may be due to a deficiency in miRNA processing as described for cancer, an enhancement of miRNA degradation, or changes in primary miRNA transcription. Studies are ongoing to address each of these possibilities.

The impact that global miRNA expression levels has on cancer progression was addressed by experimentally knocking down the expression of Drosha, DCGR8, and Dicer [@pone.0044066-Kumar1]. The resulting global repression of miRNA abundance promoted cellular transformation and tumorigenesis. It is tempting to speculate that the global decrease in miRNA abundance described here is a previously unrecognized link between cigarette smoking and lung cancer. It will be important to determine whether global miRNA expression is restored in former cigarette smokers.

In summary, this is the first study to analyze miRNA expression in human alveolar macrophages from nonsmokers and active smokers. The data show a global repression of miRNA levels in smokers. In addition, many of the downregulated miRNAs are predicted to target mRNAs that had increased expression in alveolar macrophages of smokers. This supports a role for miRNA expression in regulating disease-relevant changes in gene expression in smoker alveolar macrophages.

[^1]: **Competing Interests:**The authors have read the journal's policy and have the following conflicts. Author A.D. is now employed at Life Technologies. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

[^2]: Conceived and designed the experiments: JG TG MW MM. Performed the experiments: LP AD AR IH KK. Analyzed the data: JG AD JK MM. Contributed reagents/materials/analysis tools: JK. Wrote the paper: JG MW MM.

[^3]: Current address: Life Technologies, Eugene, Oregon, United States of America
